51 results about "Escherichia albertii" patented technology

The invention relates to a talaromyces purpureogenus strain D01 and application of the talaromyces purpureogenus strain D01, and belongs to the technical field of microorganisms. The talaromyces purpurogenus D01 disclosed by the invention is preserved in Guangdong Microbial Culture Collection Center, and the preservation number of the talaromyces purpurogenus D01 is GDMCC NO.66458. The strain is obtained by separating and purifying soil samples near exits of Guangzhou Taitai and subway stations, and tests show that bacteriostatic active substances generated by fermentation of the strain have good bacteriostatic effects on burkholderia cepacia, staphylococcus aureus, pseudomonas putida, pseudomonas aeruginosa, escherichia coli and candida albicans. And the antibacterial active substance has high temperature resistance and excellent preservative effect, can be used as an antibacterial preservative raw material to be applied to the fields of food, health care products or daily chemical products and the like, and has wide application prospects and important conversion research values.

The present invention provides a Lactiplantibacillus plantarum strain capable of resisting Streptococcus pneumoniae infection in the respiratory tract, with a deposit number of CCTCC NO: M2022359. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has a strong adhesion effect on nasal epithelial cells and can colonize in the nasal cavity; and can significantly inhibit the adhesion effect of Streptococcus pneumoniae, the main pathogenic microorganism of sinusitis, on nasal epithelial cells; it also has an inhibitory effect on the growth of most other pathogenic microorganisms of sinusitis, including β-hemolytic streptococcus, Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, etc. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has no toxic effect on the body and has good safety. It can be added to drugs for preventing respiratory diseases or improving respiratory symptoms caused by bacterial infections, and has broad application prospects.

This utility model relates to the field of microbial detection technology, and in particular to an enrichment device for Shiga toxin-producing Escherichia coli. The technical solution includes an enrichment container body, a sealing cap at the top for sealing, a shock-absorbing pad at the bottom for reducing amplitude, and a stirring structure at the top of the sealing cap for mixing the sample solution. The stirring structure includes a motor for driving the mixture, and a rotating shaft fixedly mounted at the output end of the motor. The rotating shaft passes through the sealing cap and has multiple stirring blades spirally distributed on its exterior. This utility model, through the arrangement of the motor, stirring blades, and connecting rod, allows the motor to be activated after the sample solution and enrichment solution are added. The motor drives the rotating shaft, which in turn rotates the multiple stirring blades. The stirring blades stir the two liquids, enabling a more uniform mixing of the sample solution and enrichment solution, avoiding localized excessively high or low concentrations, and improving the uniformity and efficiency of the enrichment.

The present application relates to the field of biotechnology, in particular to a carbapenem-resistant escherichia coli phage and application thereof.A new escherichia coli phage vB_EOP_Se009 is isolated and purified, and the phage has good sterilization effect on carbapenem-resistant escherichia coli.The phage has strong tolerance to temperature and pH, is high in specificity and stability, can effectively solve the problem that carbapenem-resistant escherichia coli is resistant to multiple antibiotics, and provides an experimental basis for developing a preparation for preventing or treating carbapenem-resistant escherichia coli infection in clinic, and has great clinical application potential.

The invention provides a product for detecting eight food-borne pathogenic bacteria by time-of-flight mass spectrometry, which comprises a specific primer group of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. The detection vehicle product is used for carrying out multiple PCR amplification on pathogen DNA, and the size of a fragment of the multiple PCR product is detected through MALDI-TOF MS (matrix-assisted laser desorption / ionization time of flight mass spectrometry). According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Z34B3 and application thereof. The amino acid sequence of the antibacterial peptide Z34B3 provided by the invention is shown as SEQ ID NO: 1, the secondary structure is an alpha helix, the molecular weight is small, and the antibacterial peptide Z34B3 can change the cell membrane permeability of various gram-negative bacteria including pasteurella multocida, escherichia coli and acinetobacter baumannii, inhibit the generation of cell membranes and play antibacterial and bactericidal roles. Moreover, the antibacterial peptide Z34B3 provided by the invention has low hemolytic activity and no cytotoxicity, and can be applied to preparation of products with bacteriostatic and bactericidal effects and preparation of drugs for preventing and / or treating bacterial infectious diseases. Furthermore, the C tail end of the antibacterial peptide Z34B3 is subjected to amidation modification, and compared with non-modification treatment, the stability can be improved.

Disclosed here are bacteriophage compositions for Escherichia comprising CRISPR-Cas systems and methods of use thereof.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The utility model relates to sample sampling device technical field especially, it is used for the sampling device for shiga toxin producing escherichia coli detection. Its technical scheme includes sampling cylinder and rotates and installs the rotating sampling assembly in sampling cylinder, the bottom of rotating sampling assembly is provided with the lower cover of screw thread rotation and is installed in the bottom of sampling cylinder and is closed, rotating sampling assembly includes the outer sleeve rod and sets up in the inner sleeve rod of outer sleeve rod, the bottom end of inner sleeve rod is provided with the sampling clamp for shiga toxin producing escherichia coli sampling, the sampling clamp includes the fixed rod of rotation and is installed below sampling clamp, the bottom end fixedly connected with sampling spoon of fixed rod. The utility model is accurate in sampling, avoids to contaminate, realizes the accurate, safe, convenient sampling of all kinds of samples, improves the reliability and efficiency of shiga toxin producing escherichia coli detection, provides the powerful technical support for food safety, environmental protection and disease diagnosis etc.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

The invention provides a method for detecting eight food-borne pathogenic bacteria by a time-of-flight mass spectrometry. A primer group comprises a specific primer pair combination of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. According to the method, a specific primer is used for performing multiple PCR amplification on pathogen DNA, and the size of a fragment of a multiple PCR product is detected through MALDI-TOF MS. According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.

The invention relates to the technical field of natural antibacterial compounds, in particular to an antibacterial compound, a preparation method and application thereof and a pesticide agent. The antibacterial compound is selected from compounds shown in the following structural formula: the compound has an inhibition effect on methicillin-resistant staphylococcus aureus and other drug-resistant bacteria, staphylococcus aureus, escherichia coli, salmonella, pseudomonas aeruginosa and other bacteria, and alternaria, fusarium, colletotrichum and other fungi; the compound can be applied as broad-spectrum antibacterial, broad-spectrum antifungal and drug-resistant bacterium resistant drugs.

The present application relates to the technical field of microbial separation, and particularly relates to a separation method and application of intestinal probiotic escherichia; the separation method of intestinal probiotic escherichia is to take bovine large intestine content as raw material, to realize pre-screening of potential colonization strains through mucus anaerobic targeted enrichment, then to obtain resistant colonies through bile salt-short chain fatty acid stress primary screening, to scrape the colonies with metallic luster and fluorescence quenching ring through FITC-labeled mucus fluorescence indication secondary screening, and finally to obtain target strains through multiple PCR screening of negative virulence gene-positive functional gene, to realize directional separation of intestinal probiotic escherichia after purification of nutrient agar; the present application realizes targeted enrichment of intestinal colonization bacteria, environmental tolerance pressure screening and mucus binding visualization identification, solves the problems of strong randomness of traditional probiotic screening and inability to predict colonization potential, and provides a new strategy of efficient and safe probiotic strain screening for development of functional food and microecological preparation.

The application discloses a construction method and application of recombinant escherichia coli GDH-FR-MDH, and the method comprises the following steps: taking mannitol dehydrogenase gene and glucose dehydrogenase gene as templates, using a connecting peptide to connect the two enzyme genes to an expression vector by a homologous recombination method to construct a recombinant plasmid, transforming the recombinant plasmid into competent escherichia coli, and after screening and verification, obtaining the recombinant escherichia coli GDH-FR-MDH. The recombinant escherichia coli GDH-FR-MDH is used for synthesizing mannitol. The mannitol dehydrogenase and the glucose dehydrogenase are fused and expressed by the connecting peptide, and are used as a biological catalyst for mannitol, so that the cost required by the reaction is reduced.

Presented herein are systems and methods of selecting a cancer therapy in a cancer subject. A computing system may obtain, for a subject at risk of or diagnosed with cancer, a dataset comprising genome sequence reads of a biological sample obtained from the cancer subject. The computing system may identify, from the dataset, a first portion of the genome sequence reads corresponding to candidate Escherichia reads. The computing system may filter reads corresponding to a bacteriophage from the first portion of the genome sequence reads to generate a second portion of the genome sequence reads corresponding to true Escherichia reads. The computing system may determine, using the second portion of the genome sequence reads, a score indicating a number of true reads for Escherichia. The computing system may select, from a plurality of anti-cancer therapies, the anti-cancer therapy for the cancer subject based on the score.

The invention is applicable to the technical field of microorganisms, and provides a lactobacillus paracasei Jlu-CH9 and application thereof, the lactobacillus paracasei Jlu-CH9 is preserved in China General Microbiological Culture Collection Center on January 4, 2026, the preservation number is CGMCC No.37281, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain Jlu-CH9 obtained by separation has certain tolerance to acid and cholate, has no hemolysis phenomenon, and is sensitive to various antibiotics; the compound has good inhibitory activity on dipeptidyl peptidase IV and has a certain potential of reducing blood sugar. The compound has relatively good inhibitory activity on a plurality of pathogenic bacteria including salmonella typhimurium, staphylococcus aureus, escherichia coli, clostridium perfringens and pseudomonas aeruginosa; the traditional Chinese medicine composition has good prevention and treatment effects on a DSS-induced mouse colitis model, and can repair intestinal barriers, regulate immune balance, remodel intestinal flora homeostasis and relieve colonic atrophy.

The invention relates to bacillus velezensis B02 and application of the bacillus velezensis B02, and belongs to the technical field of microorganisms. The strain is preserved in Guangdong Microbial Culture Collection Center, and the preservation number of the strain is GDMCC NO.66439. The strain is obtained by separation, purification and screening from a soil sample, and tests show that bacteriostatic active substances generated by fermentation of the strain have good bacteriostatic effects on Burkholderia cepacia, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Pseudomonas putida, Enterococcus faecalis, Candida albicans and Aspergillus brazili. And the product also has excellent heat resistance, cold resistance, illumination stability, pH stability and preservative effect, belongs to a mild low-irritation raw material, and can be used for preparing daily chemical products. Therefore, the bacillus velezensis B02 and the bacteriostatic active substances generated by the bacillus velezensis B02 have wide application prospects and important transformation research values.

The invention relates to the technical field of biology, in particular to bacteroides fragilis FMBL Ba24006 DMX for metabolism of pectic polysaccharides and application, the bacteroides fragilis FMBL Ba24006 DMX is preserved in China Center for Type Culture Collection on January 20, 2026, the preservation number is CCTCC M 2026175, the bacteroides fragilis FMBL Ba24006 DMX has good pectin metabolism capacity, pectin can be effectively used as a carbon source to achieve rapid proliferation, and meanwhile, the bacteroides fragilis FMBL Ba24006 DMX can be used for metabolism of pectic polysaccharides. The bacterial strain has a good antibacterial effect on hemorrhagic Escherichia coli; the compound is sensitive and moderately sensitive to cefoxitin and rifampicin. The strain can produce a large amount of short-chain fatty acid when being used for fermenting pectin, and fermentation liquor taking the pectin as a carbon source has relatively strong scavenging capacity on DPPH and ABTS free radicals; a relatively good inhibition effect is achieved on the activity of alpha-amylase; the method can be used for preparing antioxidant products, fermented foods, health-care products, food additives and feeds, and has a wide application prospect.

The invention relates to application of jasmine flowers in preparation of a buffalo milk product, the jasmine flower buffalo milk product and a preparation method of the jasmine flower buffalo milk product. According to the application, jasmine flowers or products of the jasmine flowers serve as bacteriostatic active substances to be applied to preparation of buffalo milk products, the products are jasmine flower extracts, jasmine tea or jasmine tea extracts, and harmful bacteria used for inhibiting comprise pseudomonas aeruginosa, escherichia coli, klebsiella pneumoniae and acinetobacter baumannii. The preparation method of the jasmine buffalo milk product comprises the following steps: adding jasmine or a product thereof as a bacteriostatic active substance into buffalo milk, filtering, homogenizing and sterilizing; and packaging to obtain the product, or adding a yoghurt leavening agent for fermentation, and packaging to obtain the product. The obtained buffalo milk product has an inhibiting effect on harmful bacteria such as pseudomonas aeruginosa, escherichia coli, klebsiella pneumoniae and acinetobacter baumannii, the microbial contamination risk of the buffalo milk product is reduced, and the buffalo milk product is a beverage with unique jasmine flower flavor and taste.

The present invention discloses a monoclonal antibody CJ116 against pathogenic Campylobacter and its application. In the monoclonal antibody CJ116, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.5. This monoclonal antibody CJ116 has high affinity and high specificity, and the detection sensitivity for Campylobacter jejuni and Campylobacter coli can reach 10<supgt;2< / supgt> CFU / mL, and the detection sensitivity for Campylobacter fetus, Campylobacter upsaliensis and Campylobacter lari is 10<supgt;3< / supgt> CFU / mL, but there is no cross-reaction with other common intestinal pathogenic bacteria such as pathogenic Escherichia coli, Salmonella enteritidis, Yersinia enterocolitica, Shigella flexneri, Shigella boydii and Staphylococcus aureus.

The invention discloses recombinant Escherichia coli producing beta-amino acid ester acyltransferase and a construction method and application thereof, the recombinant Escherichia coli is preserved in China General Microbiological Culture Collection Center, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation date is October 22, 2025, and the preservation number is CGMCC No.36299. The construction method comprises the following steps that a beta-amino acid ester acyltransferase gene DmpA-YK01 is connected to an expression vector to construct recombinant plasmids, the recombinant plasmids are transformed into competent escherichia coli, after screening and verification, the recombinant escherichia coli DmpA-YK01 is obtained, and the nucleotide sequence of the DmpA-YK01 is shown as SEQ ID NO.6. The recombinant escherichia coli DmpA-YK01 is obtained. The recombinant escherichia coli constructed by the invention can be used for producing beta-amino acid ester acyltransferase, the beta-amino acid ester acyltransferase is used for catalytic synthesis of L-carnosine, and when the concentration of a substrate L-histidine reaches 95 g / L, the conversion rate can exceed 70%.

The present invention relates to an efficient Escherichia coli phage and its application. The phage is named LYE-01, and its taxonomic name is Escherichia coliphage. The preservation number is CGMCC No. 46095, the preservation date is August 7, 2024, and the preservation institution is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms. The present invention provides a phage LYE-01 of Escherichia coli. The optimal multiplicity of infection of this phage is 1. It has strong acid resistance and thermal stability. Under the conditions of pH value 4-11, temperature 10°C-50°C, and ultraviolet irradiation within 20 minutes, this phage can maintain a high titer. The one-step growth curve experiment shows that the latent period of this phage infecting Escherichia coli is about 10 minutes, the burst period is about 40 minutes thereafter, and the stable plateau period is after 50 minutes of phage infection.

The invention discloses Escherichia coli LNT I-2 and a method for stably generating lactose-N-tetrasaccharide on a large scale by using the Escherichia coli LNT I-2. The preservation number of the Escherichia coli LNT I-2 is CCTCC NO: M 20251742, the Escherichia coli LNT I-2 is classified and named as Escherichia coli LNT I-2, the preservation date is July 31, 2025, the Escherichia coli LNT I-2 can utilize a fermentation culture medium without glycerol or without glycerol as a supplementary material to stably ferment and produce LNT at high yield, lactose hydrolysate can be adopted as an inducer to induce synthesis of a product-lactose-N-tetrasaccharide, and the yield of the LNT is increased. The method meets the requirements of green and efficient synthesis of the LNT, and is beneficial to popularization of industrial large-scale microbial fermentation production of the LNT.

The invention discloses an Escherichia coli DH5alpha-A strain and a method for degrading polychlorinated biphenyl by using the Escherichia coli DH5alpha-A strain, and relates to application of the Escherichia coli strain DH5alpha-A with the preservation number of CCTCC (China Center For Type Culture Collection) NO: M20242004 in degradation of the polychlorinated biphenyl, in particular to application of the Escherichia coli strain DH5alpha-A in degradation of the polychlorinated biphenyl and application of the Escherichia coli strain DH5alpha-A in degradation of the polychlorinated biphenyl. The polychlorinated biphenyl is a biphenyl compound with the chlorine number larger than or equal to 3 and comprises 2, 2 ', 3, 3'-tetrachlorobiphenyl or trichlorobiphenyl; the method for degrading the polychlorinated biphenyl comprises the following steps: inoculating the Escherichia coli strain DH5 alpha-A in the claim 1 into a culture medium containing the polychlorinated biphenyl for culturing, and taking the polychlorinated biphenyl as a unique or main carbon source in the culture medium. In the invention, the Escherichia coli DH5 alpha-A is successfully separated and identified by directionally screening and enriching the polluted soil around a polychlorinated biphenyl production enterprise. Compared with the conventional Escherichia coli, the Escherichia coli has a remarkable difference in polychlorinated biphenyl degradation capability.

This invention relates to the field of biomedical technology, and particularly to a multidrug-resistant Escherichia coli bacteriophage and its applications. This invention has screened an Escherichia coli bacteriophage, vB_EOP_Se004, which exhibits good killing effects against clinically isolated multidrug-resistant Escherichia coli. It also demonstrates strong tolerance to temperature and pH, maintaining stable survival rates within a pH range of 4-10 and a temperature range of -20°C to 70°C. This bacteriophage can effectively address the resistance of multidrug-resistant Escherichia coli to multiple antibiotics, offering significant advantages in the clinical treatment of infections.

The present invention provides an application and method of an Escherichia coli small RNA sRNA0004 regulatory preparation in the preparation of a kit for regulating bacterial drug resistance, and belongs to the field of genetic engineering technology. The present invention provides an application of an Escherichia coli small RNA sRNA0004 regulatory preparation in the preparation of a kit for regulating bacterial drug resistance, and the nucleotide sequence of the sRNA0004 is shown in SEQ ID NO.1. In the present invention, the Escherichia coli non-coding small RNA sRNA0004 is related to bacterial drug resistance. Overexpression of sRNA0004 will increase bacterial drug resistance, while by reducing the expression of sRNA0004, bacterial drug resistance can be reduced. The Escherichia coli small RNA sRNA0004 regulatory preparation provided by the present invention is of great significance in the field of changing bacterial drug resistance, and thus provides a way to treat infections caused by clinical drug-resistant strains.

The invention provides a yin-nourishing and lung-moistening fermentation composition and a preparation method thereof. The yin-nourishing and lung-moistening composition with efficient bacteriostatic activity is produced on the basis of a stepped fermentation process. The method comprises the following steps: firstly, carrying out first-stage fermentation on radix ophiopogonis and codonopsis pilosula by utilizing plant lactobacillus MG360; after fermenting for 12 hours, supplementing the extracts of the pears, the liquorice and the loquats and the casei paracasei ID001, and carrying out second-stage fermentation. According to the unique stepped fed-batch fermentation process, the antibacterial effect of the plantaricin EF on pneumonia-related pathogenic bacteria, including streptococcus pneumoniae, beta hemolytic streptococcus, pyogenic streptococcus, escherichia coli, staphylococcus aureus and the like, can be remarkably improved. Meanwhile, the expression of related genes pln-E and pln-F is up-regulated. Animal experiments prove that the composition has excellent effects of nourishing yin, moistening the lung, clearing away the lung-heat and resisting inflammation. The traditional medicinal and edible raw materials are combined with the modern microbial fermentation technology, and a new strategy is provided for developing novel functional products capable of nourishing yin, moistening the lung and resisting infection.

The invention provides Escherichia coli YC49 and application of the Escherichia coli YC49 in inhibiting clostridium difficile in cooperation with bacteroides, and belongs to the technical field of microorganisms. The invention provides Escherichia coli YC49, and the preservation number of the Escherichia coli YC49 is CGMCC (China General Microbiological Culture Collection Center) No. 34488. The invention also provides an effect of the Escherichia coli YC49 and bacteroides on synergistically inhibiting clostridium difficile, and further provides a compound probiotic composition, an in-vitro antibacterial product and a coprophilous fungus transplantation product. The Escherichia coli YC49 can accelerate the whole process from growth to decline of clostridium difficile, and a culture solution obtained after the Escherichia coli YC49 is combined with common bacteroides or the Escherichia coli YC49 and the common bacteroides are co-cultured can remarkably inhibit growth of early-stage clostridium difficile, so that the Escherichia coli YC49 has application significance in treatment of clostridium difficile infection.

The invention discloses a microbial marker for thyroid-associated ophthalmopathy, a product and application of the microbial marker, and belongs to the field of biological medicine. The microbial marker comprises one or more of the following components: Faecalibacterium prausnitzii, Parabacteroides sp.CT06, Escherichia coli, Alistilla finegili, and Bacteroides uniformiformis, and the microbial marker comprises one or more of the following components: the Faecalibacterium prausnitzii, the Parabacteroides sp.CT06, the Escherichia coli, the Alistilla finegili, and the Bacteroides uniformii. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the microbial marker. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.